ESC 365 - SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

ESC Premium Access

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Session: New frontiers: SGLT2 inhibitors in cardiorenal disease

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor C. Noergaard (Aalborg, DK)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Caroline Holm Noergaard

Aalborg University Hospital, Aalborg (Denmark)

0 follower

4 more presentations in this session

State of the Art - SGLT2 inhibitors in cardiovascular disease

Speaker: Professor M. Sabatine (Boston, US)

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Speaker: Doctor T. Zelniker (Vienna, AT)

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Speaker: Doctor J. Udell (Toronto, CA)

Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Speaker: Professor N. Sattar (Glasgow, GB)

Access the full session

New frontiers: SGLT2 inhibitors in cardiorenal disease

Speakers: Doctor C. Noergaard, Professor M. Sabatine, Doctor T. Zelniker, Doctor J. Udell, Professor N. Sattar

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources